Limbix
Limbix is a digital therapeutics company that developed SparkRx, a prescription mobile application for treating depression in adolescents. Founded in 2016 and based in San Francisco, it was acquired by Big Health in July 2023.
- Company typePrivate
- Founded2016
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2C
- OfferingSoftware
What Limbix does
Limbix was a San Francisco-based digital therapeutics company founded in 2016 that developed prescription software for adolescent mental health. The company's core product was SparkRx, a digital therapeutic application designed to treat depression in adolescents, which the company reported had shown positive clinical results. The platform was positioned as a frontline digital treatment option for teenage depression, targeting a narrow, underserved population with limited digital therapeutic alternatives.
Limbix operated with a lean 11-50 employee organization and concentrated its development effort on a single primary product in the adolescent mental health vertical. Its technology stack centered on mobile-delivered therapeutic content and protocols validated through clinical study, rather than on AI-driven personalization or data analytics layers. The company carried out no publicly disclosed integration, API, or SDK offerings, suggesting a direct-to-patient or provider-prescribed distribution model rather than a platform play.
Commercially, Limbix generated revenue through digital therapeutic product sales, structured as a recurring subscription model, from the commercialization of SparkRx and planned pediatric mental health offerings. The company raised approximately $31 million across six funding events between 2016 and 2021, culminating in a $15 million Series A2 led by GSR Ventures in December 2021 earmarked for commercialization and staffing. In July 2023, Limbix was acquired by Big Health Inc., a digital therapeutics provider focused on non-drug therapies, integrating SparkRx and planned teen anxiety products into Big Health's broader portfolio.
Limbix firmographics
Firmographics- Name
- Limbix
- Legal name
- Limbix Health Inc.
- Website
- https://limbix.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Limbix is a digital therapeutics company that developed SparkRx, a prescription mobile application for treating depression in adolescents. Founded in 2016 and based in San Francisco, it was acquired by Big Health in July 2023.
- Ownership category
- akta.pro rank
Limbix industry classification
Industry- Product category
- Digital Therapeutics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Condition-specific Digital Therapeutics (DTx) (HLACANAA)
- akta.pro secondary industries
- Pediatrics & Adolescent Therapeutics (Digital) (HLACANAL), Behavioral Health Digital Therapeutics (DTx) & Virtual Care Partner Management (HLAEAHAJ), DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO)
Keywords
Where Limbix is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Limbix business model
Business model- GTM type
- B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Digital Therapeutic Product Revenue: Revenue generated from commercialization of digital therapeutic products such as SparkRx for adolescent depression and potential future pediatric mental health digital therapeutics.
Limbix product offering
Product offeringCore offering
Limbix developed and commercialized SparkRx, a prescription digital therapeutic mobile application designed to treat depression in adolescents. The product was positioned as a frontline digital treatment option for teenage depression, supported by positive clinical results, and represented the company's primary offering within a focused adolescent mental health portfolio.
Product overview
Limbix is a digital therapeutic company that developed mental health treatments for adolescents. The company offers a single primary product, SparkRx, which is a digital therapeutic app designed to treat depression in teenagers. SparkRx represents the core offering within Limbix's adolescent mental health portfolio. In July 2023, Limbix was acquired by Big Health Inc., expanding Big Health's portfolio to include SparkRx for teenage depression and teen anxiety products.
Differentiator
Problem solved
Functional benefit
Products and services
- SparkRx SparkRx is a prescription digital therapeutic mobile application designed to treat depression in adolescents. It serves as a frontline digital treatment option for teenage depression, with positive clinical results supporting its efficacy. The product is intended for adolescents experiencing depression and related mental health conditions, and was integrated into Big Health's portfolio following the July 2023 acquisition.
Quantifiable outcome
- SparkRx showed positive clinical results in treating adolescent depression.
Companies that use Limbix
Customer profileSegments2 records
Ideal customer profiles2 records
Limbix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Limbix partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights4 records
Limbix competitors and assessment
Company assessmentDirect peers
- Pear Therapeutics: Pear Therapeutics was a leading prescription digital therapeutics company developing FDA-authorized software-based treatments across multiple indications including mental health. Closely comparable to Limbix in prescription DTx commercialization model and clinical-evidence-driven approach.
- Better Therapeutics: Better Therapeutics is a prescription digital therapeutics company developing software-based treatments for cardiometabolic and related conditions. Comparable to Limbix as a clinical-stage prescription DTx pursuing payer reimbursement for software-delivered therapies.
- Mahana Therapeutics: Mahana Therapeutics is a prescription digital therapeutics company focused on conditions including IBS and mental health. Comparable to Limbix in the prescription DTx category with similar regulatory and reimbursement pathways.
- Cognoa: Cognoa develops FDA-authorized digital diagnostics and therapeutics for pediatric developmental conditions such as autism. Highly comparable to Limbix as a pediatric-focused digital health company pursuing FDA-authorized digital products for children and adolescents.
- Akili Interactive: Akili Interactive is an FDA-cleared prescription digital therapeutics company whose lead product (EndeavorRx) targets pediatric ADHD. Comparable to Limbix as a prescription DTx company focused on pediatric/adolescent mental and cognitive health indications.
Emerging players
- Brightline: Brightline is a pediatric and adolescent mental health platform combining teletherapy, coaching, and digital tools. Comparable to Limbix in its exclusive focus on pediatric/adolescent mental health, though delivered via services rather than prescription software.
- BehaVR: BehaVR develops virtual reality-based digital therapeutics for mental health conditions including anxiety and depression. Comparable to Limbix as a digital therapeutics peer pursuing FDA-aligned, evidence-based software treatments for mental health indications.
Broad incumbents
- Headspace Health (Ginger): Headspace Health (formed via the Ginger-Headspace merger) is a scaled behavioral health platform offering mental health support including therapy and coaching. Overlaps with Limbix's adolescent mental health positioning as a major commercial competitor for patient and payer mindshare.
- Talkspace: Talkspace is a publicly traded virtual behavioral health platform providing therapy and psychiatry services including for adolescents. Comparable to Limbix as an adolescent-accessible mental health treatment option competing for the same clinician-prescribed treatment pathways.
- Big Health: Big Health is the digital therapeutics company that acquired Limbix in 2023. It develops prescription digital therapeutics for insomnia (Sleepio) and anxiety (Daylight) — overlapping condition-specific DTx focus and now direct portfolio adjacency to Limbix's adolescent depression asset.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Limbix social profiles
Digital presenceLimbix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Limbix leadership team
Management profileNumber of profiles
Profiles3 records
Limbix funding detail
Funding detailFunding overview
Funding rounds6 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Limbix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Limbix
What does Limbix do?
Limbix developed and commercialized SparkRx, a prescription digital therapeutic mobile application designed to treat depression in adolescents. The product was positioned as a frontline digital treatment option for teenage depression, supported by positive clinical results, and represented the company's primary offering within a focused adolescent mental health portfolio.
Is Limbix a public or private company?
Limbix is a private company. It is classified as corporate owned and is currently acquired.
When was Limbix founded?
Limbix was founded in 2016. It employs 11 to 50 people.
Where is Limbix based?
Limbix is headquartered in Palo Alto, United States, in the North America region.
How does Limbix make money?
One revenue line is on record: digital Therapeutic Product Revenue.
Who are Limbix's main competitors?
Direct peers on record are Pear Therapeutics, Better Therapeutics, Mahana Therapeutics, Cognoa and Akili Interactive. Emerging players are Brightline and BehaVR. Broad incumbents are Headspace Health (Ginger), Talkspace and Big Health.
Does Limbix have an API?
No public API is recorded for Limbix.
What industry is Limbix in?
Limbix's product category is Digital Therapeutics. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAL, Pediatrics & Adolescent Therapeutics (Digital). Its NAICS code is 334510 and its SIC code is 3841.